Rolling Out2h
Foods that help prevent kidney stones naturally
Discover the best foods to prevent kidney stones and simple dietary changes to protect your kidney health naturally.
Suni Lee: ‘I’m Not The Same Person I Was Before Kidney Disease—I’m Even Stronger’
I was in shock. Before I got sick, I didn’t really know anything about kidney disease other than that it was a serious ...
Endocrinology Advisor12h
Clinical Guidelines Updated for Evaluation, Management, Treatment of CKD
In a 2024 clinical practice guideline, researchers presented updated recommendations for the evaluation, management, and treatment of CKD.
Can food be medicine? This nonprofit says ‘yes’ — and wants it covered by more insurers
At Community Servings, a Boston-based nonprofit, the notion that “food is medicine” serves as a guiding tenant.
Rolling Out1d
What your pee reveals about your kidney health
Your pee reveals key insights about kidney health. Learn to read the signs in urine color, smell, and frequency to catch ...
Zacks Investment Research on MSN2d
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...
Study shows tirzepatide improves biomarkers in overweight, obese adults with type 1 diabetes
In a study in the journal Diabetes Technology & Therapeutics (DTT), investigators evaluated biomarkers for cardiovascular ...
MPR3d
Fabhalta Approved as First Treatment for C3 Glomerulopathy
The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.
Managed Healthcare Executive3d
FDA Approves Novartis’ Oral Fabhalta as First Treatment for C3G.
The FDA on Thursday approved Fabhalta (iptacopan) to treat complement 3 glomerulopathy (CG3), a progressive, ultrarare kidney ...
BioSpace3d
Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease
This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal ...
Fierce Pharma3d
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...